- Previous Close
350.50 - Open
349.50 - Bid 351.00 x --
- Ask 352.50 x --
- Day's Range
342.00 - 360.50 - 52 Week Range
335.50 - 632.00 - Volume
68,662 - Avg. Volume
55,878 - Market Cap (intraday)
5.236B - Beta (5Y Monthly) 0.56
- PE Ratio (TTM)
24.95 - EPS (TTM)
14.01 - Earnings Date Apr 29, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
535.00
MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, buyout. It prefers to invest in healthcare equipment and services, biotechnology, life sciences, pharmaceuticals, med tech and assistive tech companies. The firm prefers to invest in small to medium size companies that are not listed on the stock exchange and are based in Nordic region and Northern Europe. It typically invests between SEK25 million ($2.75 million) and SEK150 million ($16.51 million) with enterprise value SEK50 million ($5.90 million) and SEK250 million ($23.06 million) and sales revenue between 5 million ($5.43 million) and 25 million ($27.18 million) and EBITDA between SEK1 million ($0.11 million) and SEK50 million ($5.50 million). The firm takes minority and majority stake. It uses its capital and loans and makes balance sheet investments. MedCap AB (publ) was founded in 2001 and is based in Stockholm, Sweden.
medcap.se/en/Recent News: MCAP.ST
View MorePerformance Overview: MCAP.ST
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MCAP.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MCAP.ST
View MoreValuation Measures
Market Cap
5.24B
Enterprise Value
5.22B
Trailing P/E
24.96
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.87
Price/Book (mrq)
4.08
Enterprise Value/Revenue
2.89
Enterprise Value/EBITDA
13.19
Financial Highlights
Profitability and Income Statement
Profit Margin
11.48%
Return on Assets (ttm)
8.10%
Return on Equity (ttm)
18.08%
Revenue (ttm)
1.81B
Net Income Avi to Common (ttm)
207.4M
Diluted EPS (ttm)
14.01
Balance Sheet and Cash Flow
Total Cash (mrq)
370.1M
Total Debt/Equity (mrq)
27.79%
Levered Free Cash Flow (ttm)
213.99M